Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
doi:10.1016/j.cca.2010.08.022 Mahajan SK, Aundhakar SC
2830 Tage stabil
Patch-test recommended: Some users notice slight tinglingdiscontinue if irritation occurs
Understanding this separation helps clarify the role of CJC-1295 Ipamorelin within professional healthcare settings versus nutritional performance strategies
See Batch Specific COA Below) Form: Synthetic Peptide Powder Available in 1500mg Vials This product is intended strictly for laboratory research use only
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
US$ 21.99
US$ 27.99
US$ 29.60
US$ 25.58
